Skip to Content
Morningstar

Merck & Co Inc - Stock Quote MRK

Morningstar Rating
Rating as of

Morningstar's Merck & Co Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Undervalued Merck Posts Strong Q1, Lifted by COVID Treatment Sales and Continued Keytruda Growth

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Merck reported strong first-quarter results ahead of our projections, but we don’t expect any major changes to our fair value estimate. We view the stock as undervalued, with the market not fully appreciating the firm’s solid growth potential driven by immuno-oncology drug Keytruda, human papillomavirus vaccine Gardasil, and animal health drugs. The strong positioning of these products along with a robust portfolio and improving pipeline reinforces Merck’s wide moat.

Read Full Analysis

Merck & Co Inc's Company Profile

Business Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.

Contact
2000 Galloping Hill Road
Kenilworth, NJ, 07033
T +1 908 740-4000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Classic Growth
Employees 68,000

Merck & Co Inc's Related Articles & News

Our Picks

21 Best Healthcare Companies to Invest In

These companies largely earn their competitive advantage from intangible assets and their stocks are great choices for an investor’s watchlist.
Benjamin Slupecki
Market Update

2022 Selloff Has Left the U.S. Stock Market Undervalued

Flight to safety pushes defensive sectors too high while leaving growth stocks attractively priced.
David Sekera
Fund Spy

Funds That Buy Like Buffett, 2022

Our annual review of funds that own the same stocks as the Oracle of Omaha.
David Kathman
Investing Specialists

Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks

Half of the top 10 dividend-yielding names are undervalued.
Eden Alemayehu
Stock Strategist

Merck's Stock Is Underappreciated

The drugmaker offers investors robust growth and an attractive dividend, notes Morningstar's analyst.
Damien Conover
Stock Strategist Industry Reports

Will Vaccine Manufacturers' Windfalls Continue Beyond 2022?

We think the COVID-19 treatment market will have more longevity.
Karen Andersen
Market Update

Pullback an Opportunity to Pick Up Undervalued Stocks

Value remains attractive, but time to rotate back into growth … and even some tech.
David Sekera
Investing Specialists

Weekly Wrap: Undervalued Stocks for 2022, Outlook for the Market and Economy, and Your 2022 Financial Calendars

And also Tesla.
Morningstar.com
Quarter-End Insights

Healthcare Stocks Dogged by U.S. Policy Concerns

Large biopharma names are undervalued while device and diagnostic industries look pricey.
Damien Conover
Our Picks

33 Undervalued Stocks for 2022

Here are our analysts' top ideas in each sector for the new year.
Susan Dziubinski
Stock Analyst Update

Merck's COVID-19 Drug Posts Poor Data; No Change to FVE

Merck’s updated analysis for its coronavirus treatment, molnupiravir, could aid Pfizer’s COVID-19 treatment, Paxlovid.
Damien Conover
Our Picks

3 Warren Buffett Stocks on Sale

These undervalued stocks are among the holdings in Berkshire Hathaway today.
Susan Dziubinski
ETF Specialist

These ESG Funds Have Style

A look at how ESG integration interacts with style biases.
Lan Anh Tran
Stock Strategist Industry Reports

Big Biopharma Capital Allocation Supports Undervalued Stocks and Dividend Growth

Our top two picks in this wide-moat industry are poised to benefit.
Damien Conover
Market Update

Big Biotech Shares Take a Wild Ride

As the post-pandemic pharma landscape takes shape, Moderna and BioNTech slide, Pfizer rallies.
Jakir Hossain
Stock Analyst Update

Pfizer Posts Strong Data on COVID Drug Paxlovid

We don’t expect any major change to our fair value estimate or the fair values for firms with competing COVID treatments, including Merck.
Damien Conover
Stock Analyst Update

Merck's Growth Potential Remains Underappreciated

The wide-moat company reported a strong third quarter, but we don't expect any significant changes to our fair value estimate.
Damien Conover
Our Picks

10 Scary Stocks: 2021 Edition

These are the most overpriced stocks in our coverage universe today.
Susan Dziubinski
Market Update

What to Watch for in This Week's Earnings Reports

Keep an eye on what companies are saying about inflation and supply disruptions.
David Sekera
Commentary

The Week Ahead: Facebook, Apple, and Amazon.com to Report Earnings

Other big names, including Coca-Cola, Ford, and Exxon Mobil, will be reporting, too.
Carole Hodorowicz